Keros Therapeutics, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Keros Therapeutics' board approved a $5 million share repurchase program on September 8, 2026, following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals under the elritercept license agreement, triggered by dosing the first patient in the ELRiSE MDS clinical trial. The repurchase program is discretionary and may be modified, suspended, or discontinued at any time; timing and amount depend on market conditions and other factors.
Why this rating
Repurchase is 1.1% of market cap; milestone validates partnership but repurchase is non-binding, discretionary, and represents capital allocation rather than operational change.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.